Differential gene expression patterns between smokers and non-smokers: Cause or consequence? by Vink, J.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/167468
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Differential gene expression patterns between smokers
and non-smokers: cause or consequence?
Jacqueline M. Vink1,2,5,†, Rick Jansen2,3†, Andy Brooks4, Gonneke Willemsen1,5,
Gerard van Grootheest3, Eco de Geus1,5, Jan H. Smit3, Brenda W. Penninx2,3,5
& Dorret I. Boomsma1,2,5
Department of Biological Psychology, VU University, Amsterdam, The Netherlands1, Neuroscience Campus Amsterdam, VU University Medical Center,
Amsterdam, The Netherlands2, Department of Psychiatry/GGZ in Geest, VU University Medical Center, Amsterdam, The Netherlands3, Department of Genetics,
Rutgers University, New Brunswick, New Jersey, USA4 and EMGO Institute for Health and Care Research, Amsterdam, The Netherlands5
ABSTRACT
The molecular mechanisms causing smoking-induced health decline are largely unknown. To elucidate the molecular
pathways involved in cause and consequences of smoking behavior, we conducted a genome-wide gene expression study
in peripheral blood samples targeting 18238 genes. Data of 743 smokers, 1686 never smokers and 890 ex-smokers were
available from two population-based cohorts from the Netherlands. In addition, data of 56 monozygotic twin pairs
discordant for ever smoking were used. One hundred thirty-two genes were differentially expressed between current
smokers and never smokers (P<1.2×106, Bonferroni correction). The most signiﬁcant genes were G protein-coupled
receptor 15 (P<1×10150) and leucine-rich repeat neuronal 3 (P<1×1044). The smoking-related genes were enriched
for immune system, blood coagulation, natural killer cell and cancer pathways. By taking the data of ex-smokers into
account, expression of these 132 genes was classiﬁed into reversible (94 genes), slowly reversible (31 genes), irreversible
(6 genes) or inconclusive (1 gene). Expression of 6 of the 132 genes (three reversible and three slowly reversible) was
conﬁrmed to be reactive to smoking as they were differentially expressed in monozygotic pairs discordant for smoking.
Cis-expression quantitative trait loci for GPR56 and RARRES3 (downregulated in smokers) were associated with
increased number of cigarettes smoked per day in a large genome-wide association meta-analysis, suggesting a
causative effect of GPR56 and RARRES3 expression on smoking behavior. In conclusion, differential gene expression
patterns in smokers are extensive and cluster in several underlying disease pathways. Gene expression differences seem
mainly direct consequences of smoking, and largely reversible after smoking cessation. However, we also identiﬁed
DNA variants that may inﬂuence smoking behavior via the mediating gene expression.
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INTRODUCTION
The molecular mechanisms causing smoking-induced
health decline are largely unknown. Associations between
gene expression and smoking behavior have been observed
in multiple tissues (airway epithelial cells, alveolar mac-
rophages, leucocytes, lymphocytes, B cells, monocytes
and in whole blood). With one exception (n=1240)
(Charlesworth et al. 2010), all studies had relatively small
sample sizes (n<200) (Spira et al. 2004; Heguy et al.
2006; Beane et al. 2007; Lodovici et al. 2007;
Charlesworth et al. 2010; Pan et al. 2010; Beineke
et al. 2012; Paul & Amundson 2014). Gene expression
studies can help elucidating the molecular pathways
involved in the etiology and consequences of smoking
behavior.
Most studies explored differential gene expression
patterns for smoking by comparing gene expression in
current smokers with never smokers. Reversibility of
gene expression due to smoking can be addressed when
ex-smokers are also included. Reversible genes are differ-
entially expressed between current and ex-smokers, but
not between ex-smokers and never smokers (Beane
et al. 2007). If a gene shows a reversible gene expression
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pattern, this might suggest that the gene expression pat-
tern is a reaction to smoking (a reactive gene expression).
This does not have to be the case: the higher expression
in the current smokers compared with non-smokers could
be the result of a higher genetic liability to smoking behav-
ior, making a personmore vulnerable to start smoking and
continue smoking (causative gene expression).
When studying gene expression associations with
smoking behavior in a cross-sectional design, reactive and
causative gene expression cannot easily be distinguished.
By studying monozygotic (MZ) twin pairs discordant for
smoking, reactive genes may be detected, as differential
gene expression between a smoking MZ twin and the genet-
ically identical non-smoking co-twin cannot be caused by
differences in genetic liability, and the differential expression
is therefore likely to be reactive to smoking (van Leeuwen
et al. 2007). Studying expression quantitative trait loci
(eQTLs) may identify causative gene expression. When dif-
ferential expression between smokers and non-smokers is
associated with DNA variants that also inﬂuence smoking
behavior, this inﬂuencemay bemediated by gene expression
(which is therefore likely to be causative for smoking).
In the present study, we analyze micro-array gene
expression measurements in peripheral blood in two Dutch
cohorts (Jansen et al. 2014; Wright et al. 2014). First, we
aim to identify genes with differential expression between
743 current smokers and 1686 never smokers. Second,
we aim to determine the reversibility of the identiﬁed genes
by comparing the gene expression levels of current and
never smokers with the gene expression levels of 890 ex-
smokers. The third aim is to classify the expression of the
identiﬁed genes as reactive or causative for smoking, using
the MZ twins and eQTL lookups in the Tobacco and Genetic
Consortium (TAG Consortium 2010) genome-wide associa-
tion (GWA) study for smoking behavior. This is the ﬁrst
large-scale gene expression study for smoking in peripheral
blood combining these different approaches.
METHODS
Subjects
Two projects supplied data for this study: the Netherlands
Twin Register (NTR) (Willemsen et al. 2010) and the
Netherlands Study of Depression and Anxiety (NESDA)
(Spijker et al. 2004). Both studies were approved by the
Central Ethics Committee on Research Involving Human
Subjects of the VU University Medical Center, Amsterdam
[Institutional Review Board (IRB) number IRB-2991
under Federalwide Assurance 3703; IRB/institute codes,
NESDA 03-183; NTR 03-180], and all subjects provided
written informed consent. The sample consisted of 3109
participants from NTR and 1962 from NESDA. The age
ranged from 18 to 88 years (mean 38, standard deviation
13), and 65 percent of the sample was female. Data were
used of 2892 individuals (from 1433 families) from the
NTR and 427 unrelated participants from NESDA. NESDA
participants without data on blood counts (n=1535)
were excluded. In addition, data of 56 MZ twin pairs dis-
cordant for smoking were available from the NTR. eQTL
lookup was performed using data of 5071 subjects
(3109 NTR and 1962 NESDA participants) for which
both genotype and gene expression data were available.
Measures
Information on smoking behavior was obtained during
the home visit for blood collection as part of the NTR
biobank project (2004–2008). Participants were asked
whether they were current smokers, ex-smokers or never
smokers. For current smokers, the number of cigarettes
smoked per day was obtained, and for ex-smokers, the
time since quitting (in years). Subjects who exclusively
smoked pipe or cigar were excluded. Data were veriﬁed
by linking this information to survey data available from
the longitudinal survey study of the NTR (Supporting
Information Method A). For NESDA subjects, information
on smoking was obtained during the day of blood sam-
pling as part of the face-to-face baseline interview. Sex,
age at the time of blood draw, body mass index (weight/
height squared in kg/m2) at the time of blood draw,
lymphocyte count, monocyte count, neutrophil count,
eosinophil count, basophil count and blood hemoglobin
(mmol/l) were extracted from NESDA and the NTR data-
bases (Jansen et al. 2014; Wright et al. 2014). In addi-
tion, cotinine levels were available for 612 of 743
current smokers.
RNA extraction
The blood sampling and RNA extraction procedures have
been described in detail previously (Willemsen et al.
2010; Jansen et al. 2014; Wright et al. 2014). In short,
for NTR, venous blood samples were drawn between 7
and 10AM after an overnight fast. Within 20minutes of
sampling, heparinized whole blood was transferred into
PAXgene Blood RNA tubes (Qiagen, Valencia, Florida,
USA) and stored at 20°C. The PAXgene tubes were
shipped to the Rutgers University Cell and DNA Reposi-
tory (http://www.rucdr.org). RNA was extracted using
Qiagen Universal liquid handling system (PAXgene extrac-
tion kits from manufacturer’s protocol). Total RNA was
measured by spectroscopy (Trinean DropSense,
GentBrugge, Belgium) to determine purity and concentra-
tion; RNA ﬁdelity was measured by the (Agilent
Bioanalyzer, Santa Clara, California, USA) analysis.
From NESDA subjects, venous whole-blood samples
were obtained between 8 and 10AM, after overnight
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fasting. Between 10 and 60minutes after blood draw,
2.5ml of heparinized blood was transferred into PAXgene
tubes. This tube was kept at room temperature for a min-
imum of 2 hours and then stored at 20°C. Average time
between blood sampling and RNA extraction was
113weeks. Total RNA was extracted according to the
manufacturer’s protocol (Qiagen) (Spijker et al. 2004).
Gene expression
Gene expression was assessed at the Rutgers University
Cell and DNA Repository. Samples were randomly
assigned to plates. For cDNA synthesis, 50 ng of RNA
was reverse transcribed and ampliﬁed in a plate format
on a Biomek FX liquid handling robot (Beckman Coulter,
Brea, California, USA) using Ovation Pico WTA reagents
per the manufacturer’s protocol (NuGEN, San Carlos,
California, USA). Products puriﬁed from single-primer iso-
thermal ampliﬁcation were then fragmented and labeled
with biotin using Encore Biotin Module (NuGEN). Prior
to hybridization, the labeled cDNA was analyzed using
electrophoresis to verify the appropriate size distribution
(Caliper AMS90, HT DNA 5K/RNA LabChip). Samples
were hybridized to Affymetrix U219 array plates
(GeneTitan, Affymetrix, Santa Clara, California, USA).
The U219 array contains 530467 probes for 49 293
transcripts. All probes are 25 bases in length and
designed to be ‘perfect match’ complements to a desig-
nated transcript. Array hybridization, washing, staining
and scanning were carried out in an Affymetrix
GeneTitan System per the manufacturer’s protocol.
Gene expression quality control
Gene expression data were required to pass standard
Affymetrix quality control metrics (Affymetrix expression
console). Probes were removed when their location was un-
certain or if their location intersected a polymorphic single-
nucleotide polymorphism (SNP), leaving 44241 probe sets
for analysis. Expression values were obtained using robust
multi-array average normalization implemented in
Affymetrix Power Tools (v 1.12.0). Data for samples that
displayed an average Pearson correlation below 0.8 with
the probe set expression values of other samples and samples
with incorrect sex chromosome expression were removed.
Statistical analyses
1a. Differential gene expression between current smokers and
never smokers
Linear mixed models were used to explore differences in
gene expression patterns between current smokers
(n=743) and never smokers (n=1686) while correcting
for family relatedness (Visscher, Benyamin, & White
2004). For each of the 44241 probe sets, a mixed model
was ﬁtted with gene expression as dependent variable
and smoking status (current versus never) as indepen-
dent variable. Fixed-effect covariates included in the ﬁnal
model were sex, age at the time of blood draw, body mass
index, lymphocyte count, monocyte count, neutrophil
count, eosinophil count, basophil count, average correla-
tion between arrays, hemoglobin (mmol/l), cohort (NTR
or NESDA), time of blood sampling, month of blood sam-
pling, time between blood sampling and RNA extraction
and the time between RNA extraction and RNA ampliﬁ-
cation. Random effects were plate, well, family ID and
zygosity. Non-signiﬁcant covariates were not included in
the ﬁnal model: depression status (DSM-IV depression
yes/no), psychotropic medication (yes or no), alcohol
use (≥12 glasses of alcohol per week versus <12 glasses
per week or not drinking), education level (low, moderate
or high), time between RNA ampliﬁcation and RNA frag-
mentation and time between RNA fragmentation and
RNA hybridization. Mixed models and P-values were
computed using the R function lmer from the package
lme4. To correct for multiple testing, a Bonferroni correc-
tion was applied (P<0.05/44 241=1206). The genes
differentially expressed between current and never
smokers are called ‘smoking-related genes’ throughout
the rest of the manuscript.
1b. Pathway analyses of smoking-related genes. We used
Fisher’s exact test to explore whether gene categories
were enriched among the identiﬁed smoking-related
genes. We used gene categories from Gene Ontology Bio-
logical Process (GOBP), Kyoto Encyclopedia of Genes and
Genome (KEGG) and Ingenuity Pathway Analysis (IPA).
KEGG, GOBP and IPA have overlapping but also unique
gene categories. GOBP does not contain disease gene cate-
gories, but KEGG and IPA do. GOBP covers many biological
processes not covered by KEGG and IPA. KEGG contains
strongly curated pathways, whereas IPA provides more
broadly deﬁned categories. IPA provides P-values and cor-
responding false discovery rates (FDRs) for enrichment.
For the GOBP and KEGG pathways, the statistical software
package Rwas used. GOBP categories were retrieved using
the R package org.Hs.eg.db (version 2.10.1). KEGG path-
ways were downloaded from http://www.broadinstitute.
org/gsea/downloads.jsp (c2.cp.kegg.v4.0.entrez.gmt). The
reference set and the gene set were deﬁned separately for
KEGG and GOBP analysis. In total, 9902 GOBP and 186
KEGG categories contained one or more genes measured
by the U219 microarrays. The gene set with smoking-
related genes was tested for enrichment (separately for
upregulated and downregulated genes) in categories with
more than one gene overlap. The P-value from the exact
test is the chance that the overlap between the gene set
and the gene category is not larger than for random gene
sets of this size within the reference set. For the P-values
derived from these tests, the FDR was computed.
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2. Reversibility of the associations between smoking and gene
expression
2a. Smoking status. To explore reversibility of associations
between smoking and gene expression, for the smoking-
related genes, pairwise comparisons of gene expression
levels were made using mixed models as described in item
1a. The pairwise comparisons (in addition to current
smokers versus never smokers) were current (n=743)
versus ex-smokers (n=890) and ex-smokers versus never
smokers (n=1686). For signiﬁcance, we used the thresh-
old FDR <5 percent (only correcting for tests performed
for smoking-related genes).
Reversibility was considered:
Reversible genes (gene expression current> ex=never):
if genes differed in gene expression level between current
and non-smokers (ex-smokers or never smokers) but were
similar between ex-smokers and never smokers
Slowly reversible genes (gene expression cur-
rent> ex>never): if the expression pattern was different
between current and ex-smokers but also between ex-
smokers and never smokers
Irreversible genes (gene expression current=
ex>never): if gene expression was the same in current
and ex-smokers but differed between ever (current and
ex) and never smokers
2b. Time since quitting smoking. Gene expression levels of
ex-smokers who quit smoking more than 5 years ago
(long-term quitters) were compared with ex-smokers
who quit 5 years ago or less. We expect the gene expres-
sion levels of long-term quitters to be closer to non-
smokers than for short-term quitters. Time since quitting
was also analyzed as a continuous variable, to check for a
linear relationship between level of gene expression and
time since quitting.
2c. Cigarettes per day. To explore the association between
number of cigarettes per day and gene expression levels,
gene expression levels of three groups of current smokers
were compared: smokers who smoked more than 20 cig-
arettes per day (heavy smokers), smokers who smoked
10–19 cigarettes per day (moderate smokers) and
smokers who smoked less than 10 cigarettes per day
(light smokers). Cigarettes per day was also analyzed as
a continuous variable, to check for a linear relationship
between level of gene expression and time since quitting.
In addition, cotinine levels were analyzed as biomarker
for quantity smoked.
3. Reactive versus causative expression of smoking-related
genes?
3a. Comparison of gene expression in MZ twin pairs discor-
dant for smoking. Discordant MZ twin pairs were
selected: one twin never smoked, and the other was a
current smoker at the time of blood sampling (n=56
pairs). First gene expression was residualized using all co-
variates also used for the mixed models (excluding sex
and age as MZ twin pairs have the same sex and age).
The residuals were used in a paired t-test comparing
smoking twins with their non-smoking co-twins for the
132 smoking-related genes.
3b. eQTL analysis. Previous eQTL analysis using NESDA
and NTR sample subsets were described elsewhere
(Jansen et al. 2014; Wright et al. in press). For each of the
smoking-related genes (result from 1a), the local DNA
variant with the strongest association (the top cis-eQTL
SNP, FDR<0.05) and strongest global association (the
top trans-eQTL SNP, FDR<0.05) were selected. For these
SNPs, the P-values for association with ever smoking and
cigarettes per day in meta-GWA analysis of the TAG Con-
sortium (2010) were retrieved and checked for signiﬁ-
cance (FDR correction based on the selected P-values
only).
RESULTS
Characteristics of the sample
In the ex-smoking and never smoking groups, the per-
centage of women and the mean age is higher com-
pared with that of the group of current smokers.
Importantly, neutrophil (P=1.1×1040), monocyte
(P=1.7×1034), lymphocyte (P=1.2×1030) and eosin-
ophil (P=9.4×1014) counts differed between current
smokers and never smokers. Blood subcell constitution has
a major impact on whole-blood gene expression, and thus,
blood cell counts are major confounders when identifying
smoking-associated gene expression differences. The charac-
teristics of the participants are summarized in Supporting In-
formation Table S1.
1a. Differential gene expression levels in smokers compared
with never smokers. We identiﬁed 220 probe sets targeting
132 genes (from 44241 probe sets targeting 18 238
genes) differentially expressed between current smokers
and never smokers (P<1.13×1006, Bonferroni correc-
tion). For each gene, we selected the probe set most signif-
icantly associated with smoking for further comparisons.
In total, 66 percent of the 132 genes were downregulated
in smokers. The most signiﬁcant results were found for G
protein-coupled receptor 15 (GPR15, P<10150) and
leucine-rich repeat neuronal 3 (LRRN3, P<1044),
which were both upregulated in smokers compared with
never smokers (Fig. 1).
The top 25 genes (Table 1) differentially expressed in cur-
rent smokers compared with never smokers is shown in
Table 2, and the complete list of the 132 smoking-related
genes can be found in Supporting Information Figure S1.
The expression of the 132 identiﬁed genes were not sig-
niﬁcantly associated with age * smoking interaction ef-
fects. All subsequent analyses were only carried out
with the 132 smoking-related genes.
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Figure 1 Gene expression
distribution in current smokers
(pink) and never smokers (blue)
for the most signiﬁcant genes:
GPR15 and LRRN3. [Colour
ﬁgure can be viewed at
wileyonlinelibrary.com]
Table 1 Top 25 genes differentially expressed between current smokers and never smokers.
Gene Full gene name Location Type P-value Beta
GPR15 G protein-coupled receptor 15 Plasma membrane G protein-coupled receptor 2.10e151 0.7289
LRRN3 Leucine-rich repeat neuronal 3 Extracellular space Other 4.70e45 0.4167
S1PR5 Sphingosine-1-phosphate receptor 5 Plasma membrane G protein-coupled receptor 2.20e29 0.3186
PID1 Phosphotyrosine interaction
domain containing 1
Cytoplasm Other 9.20e24 0.2221
FGFBP2 Fibroblast growth factor binding
protein 2
Extracellular space Other 3.50e22 0.3856
TBX21 T-box 21 Nucleus Transcription regulator 4.50e22 0.2564
TRDC T-cell receptor delta constant Unknown Unknown 1.80e20 0.3153
PRSS23 Protease, serine, 23 Extracellular space Peptidase 1.30e19 0.3032
NKG7 Natural killer cell group 7 sequence Plasma membrane Other 2.00e19 0.2380
CCR4 Chemokine (C–C motif) receptor 4 Plasma membrane G protein-coupled receptor 6.40e19 0.2091
SPON2 Spondin 2, extracellular matrix protein Extracellular space Other 2.10e18 0.2885
GPR56 G protein-coupled receptor 56 Plasma membrane G protein-coupled receptor 2.30e18 0.2756
KLRD1 Killer cell lectin-like receptor subfamily
D, member 1
Plasma membrane Transmembrane receptor 3.10e18 0.2704
CHST2 Carbohydrate (N-acetylglucosamine-6-O)
sulfotransferase 2
Cytoplasm Enzyme 1.40e17 0.2472
CLDND1 Claudin domain containing 1 Plasma membrane Other 2.30e17 0.1460
PRF1 Perforin 1 (pore forming protein) Cytoplasm Other 2.80e17 0.2192
GZMH Granzyme H (cathepsin G-like 2, protein
h-CCPX)
Cytoplasm Peptidase 1.80e16 0.3975
GPR55 G protein-coupled receptor 55 Plasma membrane G protein-coupled receptor 2.00e16 0.2000
FCRL6 Fc receptor-like 6 Plasma membrane Other 1.90e15 0.3178
MAL Mal, T-cell differentiation protein Plasma membrane Transporter 2.70e15 0.1524
TGFBR3 Transforming growth factor, beta
receptor III
Plasma membrane Kinase 4.70e15 0.2847
GZMA Granzyme A (granzyme 1, cytotoxic
T lymphocyte-associated serine
esterase 3)
Cytoplasm Peptidase 4.80e15 0.2388
LGR6 Leucine-rich repeat containing
G protein-coupled receptor 6
Plasma membrane G protein-coupled receptor 9.50e15 0.1952
PYHIN1 Pyrin and HIN domain family,
member 1
Nucleus Other 3.60e14 0.1606
TNFRSF13B Tumor necrosis factor receptor
superfamily, member 13B
Plasma membrane Transmembrane receptor 1.30e13 0.3235
Beta = effect size, a negative beta (italics) reﬂects a gene that is downregulated in smokers compared with never smokers, while a positive beta (bold)
reﬂects a gene that is upregulated; Location = the location in the cell where the gene product is present; P-value = P-value of the test comparing gene
expression level in current smokers with never smokers; Type = type of gene product.
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1b. Smoking-related genes enrich several biological path-
ways. The 132 smoking-related genes were tested for enrich-
ment of GOBP, KEGG or IPA pathways. The upregulated and
downregulated genes were explored separately.
The 84 downregulated genes were enriched for 63 GOBP
categories (FDR<0.05) including immune system process
(26 genes overlap with this category, FDR=6.2e4) and
blood coagulation (11 genes overlap, FDR=5.3e3) and
for 2 KEGG pathways (natural killer cell-mediated cyto-
toxicity) (6 genes overlap, FDR=1e2) and graft-versus-
host disease (3 genes overlap, FDR=3.2e02, Supporting
Information Table S3). Using IPA, we identiﬁed 15 canon-
ical pathways enriching the downregulated genes
(FDR<0.1), including natural killer cell signaling (7 genes
overlap, FDR=0.01) and sperm motility (4 genes overlap,
FDR=0.07), 379 disease and biofunctions (FDR<0.05),
including asthma (8 genes overlap, FDR=1.23e4) and
rheumatic disease (21 genes overlap, FDR=1.01e4), and
3 tox functions (FDR<0.05), including liver cirrhosis
(5 genes overlap, FDR=4.88e02) and cardiac infarction
(5 genes overlap, FDR=4.88e02).
The 48 upregulated genes were enriched for 239 GOBP
categories (FDR<0.05) including immune system process
(23 genes overlap with this category, FDR=1.3e7) and
leukocyte differentiation (11 genes overlap, FDR=1.3e6)
and for 7 KEGG pathways including colorectal cancer
[4 genes overlap (BCL2, LEF1, TCF7 and MYC),
FDR=3.8e3] and acute myeloid leukemia [3 genes over
lap (LEF1, TCF7 andMYC), FDR=3.8e3, Supporting Infor-
mation Table S3]. Also, 8 canonical pathways from IPAwere
enriched (FDR<0.1, including thyroid cancer and acute
myeloid leukemia signaling), 461 disease and biofunctions
(FDR<0.05, including quantity of leukocytes and develop-
ment of tumor) and 25 tox functions (including inﬂamma-
tion of liver, Supporting Information Table S3).
The GOBP categories enriched for downregulated genes
overlap for 33 percent with the GOBP pathways enriched
for upregulated genes (21 GOBP categories overlap), indi-
cating that upregulated and downregulated genes are in-
volved in unique (e.g. blood coagulation and cancer) but
also shared pathways (like immune system processes).
2a. Smoking status. Of the 132 smoking-related genes,
gene expression levels were signiﬁcantly different in 125
genes when comparing current smokers and ex-
smokers, while 37 of the 132 genes were differentially
expressed between ex-smokers and never smokers
(FDR<0.05, corrected for 132 tests, Supporting Infor-
mation Table S2).
In the total group of 132 smoking-related genes, the
gene expression levels of 94 genes were reversible
(gene expression current> ex=never), 31 genes were
found to be slowly reversible (gene expression
current> ex>never) and 6 irreversible (gene expression
current = ex>never): LEF1, ADAMTS1, CST7, CCR7,
GNB2L1 and SFXN1. The reversibility of one gene was
inconclusive.
The mean gene expression levels of ex-smokers tend to
be in between those of never and current smokers
(Fig. 2). In general, gene expression levels of ex-smokers
were closer to the levels of never smokers than to the
levels of current smokers.
2b. Time since quitting smoking. The gene expression
levels of long-term quitters (>5 years ago) are often more
similar to those of the non-smokers than short-term quit-
ters (≤5 years ago, Fig. 3). We also analyzed the time
since quitting as a continuous variable in the ex-
smokers. Of the 132 smoking-related genes, the gene
expression levels of 15 genes were signiﬁcantly associated
with the time since quitting (FDR<5 percent, 132 tests,
Supporting Information Table S1).
2c. Cigarettes per day. Most of the 132 smoking-related
genes show a stronger effect (Fig. 3) on gene expression
Table 2 Gene ontology (GO) pathway analysis in Panther for the 132 genes (n=124 available in Panther) that are differentially
expressed in current smokers compared with never smokers.
Biological process n Genes total n 124 genes n Expected P-value
Immune response 653 31 4.81 1.34e14
Immune system process 2283 49 16.80 1.17e10
Response to stimulus 1610 40 11.85 4.25e10
Natural killer cell activation 110 9 0.81 2.66e05
Response to interferon-gamma 108 8 0.79 2.77e04
Signal transduction 3861 52 28.41 3.33e04
Cell communication 4063 53 29.90 6.74e04
Blood coagulation 261 11 1.92 7.14e04
Response to external stimulus 261 11 1.92 7.14e04
Cell adhesion 1236 24 9.10 1.86e03
Biological process = GO category; n Expected = number of expected genes out of the 84 smoking-related genes to be member of this GO category if based
on chance; n Genes total = total number of genes that are member of this GO category; n 124 genes = number of genes out of the 84 smoking-related
genes that are member of this GO category; P-value = P-value for enrichment.
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in the heavy smokers (20+ cigarettes per day) compared
with the moderate (10–19 cigarettes per day) or light
smokers (<10 cigarettes per day), suggesting an association
Figure 2 Mean expression levels in smokers, ex-smokers and never
smokers for the 132 smoking-related genes (listed on the right) that
are differentially expressed between current and never smokers. Gra-
dation from red through orange and yellow to white reﬂects the
amount of gene expression, with red reﬂecting high gene expression
and white reﬂecting low gene expression. [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
Figure 3 Mean expression in six groups (never smokers, ex-
smokers who quit more than 5 years ago, ex-smokers who quit
5 years ago or less, current smokers who smoke less than 11 ciga-
rettes per day, current smokers who smoke 10–20 cigarettes per
day and current smokers who smoke more than 20 cigarettes per
day) for the 132 candidate genes that are differentially expressed be-
tween current and never smokers. Gradation from red through or-
ange and yellow to white reﬂects the amount of gene expression,
with red reﬂecting high gene expression and white reﬂecting low gene
expression. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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between dose and gene expression levels. To quantify this
association, we analyzed the number of cigarettes per day
as a continuous variable. Of the 132 smoking-related genes,
the gene expression levels of 28 genes (including the top hits
GPR15 and LRRN3) were signiﬁcantly associated with the
number of cigarettes per day. In addition, 10 genes (six over-
lapping with the cigarettes per day analyses) were signiﬁ-
cantly associated with cotinine levels, including the top hits
GPR15 and LRRN3 (Supporting Information Table S2).
3a. Gene expression reactive to smoking identiﬁed in MZ dis-
cordant twin pairs Of the 132 smoking-related genes, six
genes were differentially expressed in the MZ pairs discor-
dant for current smoking: GPR15, PF4, TTC38,
ACO63977.1, ALAS2 and EIF2AK1. Those genes can be
considered to show reactive gene expression. The effects
in the discordant MZ twin pairs are in the same
direction for 75 percent of the genes, compared with the
effects in the total population, which suggests more
genes may likely be reactive genes (Supporting Informa-
tion Fig. S2C).
3b. eQTLs underlying smoking-related genes whose expres-
sion is associated with smoking behavior. For each of the
132 smoking-related genes that were differentially
expressed between smokers and never smokers, the top
cis-eQTL SNP and the top trans-eQTL were selected. Of
the 132 smoking-related genes, 106 have a local cis-eQTL
and 60 a trans-eQTL. For these SNPs, the P-values for as-
sociation with ever smoking and cigarettes per day in the
meta-GWA analysis of the TAG Consortium (2010) were
gathered and checked for signiﬁcance. We identiﬁed two
top cis-eQTL SNPs that were signiﬁcantly associated with
the number of cigarettes smoked per day (rs8058865 at
GPR56, P=6.475×105, and rs10897430 at RARRES3,
P=9.3×104) in TAG.
In our study, the T allele of rs8058865 in GPR56 is
associated with decreased expression of GPR56
(P=9.6 ×1028). GPR56 expression is lower in smokers
compared with never smokers (P=2×1018).
The TAG meta-analyses results showed that the T allele
is associated with increased number of cigarettes per
day (ß = 0.347, P=6.475×105). Together, this sug-
gests that the association between this allele and
smoking quantity may be mediated by decreased ex-
pression of GPR56. However, we did not observe an
association between GPR56 gene expression levels
and cigarettes smoked per day in current smokers
(P=0.54).
Likewise, the C allele of rs10897430 in RARRES3 is
associated with decreased expression of RARRES3
(ß =0.062, P=5.6 × 108). The TAG results show
that this SNP is associated with increased number of
cigarettes per day (ß = 0.0075, P=0.0009). This
suggests that the association between the RARRES3
allele and smoking quantity is mediated by decreased
expression of RARRES3. However, we did not observe
an association between RARRES3 gene expression
levels and number of cigarettes per day in our sample
of current smokers.
None of the other eQTL SNPS from the set of 132
smoking-related genes were signiﬁcantly associated
with smoking behavior in TAG (Supporting Informa-
tion Table S4).
DISCUSSION
The present study is the largest investigation of gene
expression levels in peripheral blood of smokers and
non-smokers to date. The results revealed 132 differen-
tially expressed genes in current smokers compared with
non-smokers. These smoking-related genes were enriched
for several disease-related pathways. Expression of most of
these genes is likely to be reactive to smoking as can be
derived from integrating data from MZ twin and
ex-smokers. However, using eQTL analysis, we identiﬁed
two SNPs (rs8058865 in GPR56 and rs10897430 in
RARRES3) that may inﬂuence smoking behavior through
intermediate gene expression.
Most previous studies investigating gene expression
patterns in relation to smoking were carried out in rela-
tively small samples (Spira et al. 2004; Heguy et al.
2006; Beane et al. 2007; Lodovici et al. 2007;
Charlesworth et al. 2010; Pan et al. 2010; Beineke et al.
2012; Wright et al. in press). So far, 1 larger study is
published including 1240 individuals (Charlesworth
et al. 2010). They detected 323 genes (FDR 5 percent)
whose expression levels in lymphocytes were signiﬁcantly
correlated with smoking behavior. In total, 54 of the 323
genes were also present in our list of 132 smoking-related
genes (=41 percent of our genes). In a smaller study
(n=209 subjects + 180 subjects for replication), a ﬁve-
gene predictive model for smoking status in whole blood
was developed (Beineke et al. 2012), and three of the ﬁve
genes (LRRN3, CLDND1 and LEF1) were also found in
our list of 132 smoking-related genes. This conﬁrms that
the differential gene expression in smokers is a robust
ﬁnding. In contrast, there was no overlap between the
genes expressed in airway epithelial cells of smokers versus
non-smokers and the 132 smoking-related genes detected
in our study using peripheral blood. This might point to
tissue-speciﬁc gene expression: smoking a cigarette might
inﬂuence the expression of other genes in lung tissue com-
pared with blood cells.
To rule out the possibility that the effects we found are
merely due to difference in general health between current
smokers and non-smokers, we added a variable reﬂecting
overall health status to the model. Betas and P-values for
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smoking status were highly correlated between models with
and without the health variable (Spearman’s rho=0.99 and
0.91, respectively; data not shown), indicating that health
variables are unlikely to explain the observed associations
between smoking status and gene expression.
Pathway analyses of the 132 smoking-related genes
showed that both the upregulated and downregulated
genes are involved in the immune response, the immune
system and natural killer cell activation. It is well known
that inﬂammatory cells produce a variety of mediators in
response to smoking (Sopori 2002; Rom et al. 2013). It
has been speculated that many of the health conse-
quences of chronic inhalation of cigarette smoke might
be due to its adverse effects on the immune system
(reviewed by Rom et al. 2013). In addition, the downreg-
ulated genes were involved in blood coagulation, asthma
and cardiac infarction, while the upregulated genes were
part of cancer pathways. The expression of some well-
known cancer genes, like MYC and LEF1, was upregu-
lated in smokers compared with never smokers. LEF1
codes for a lymphoid enhancer-binding factor 1, which
is located in the nucleus, and the protein encoded by
MYC is a multifunctional, nuclear phosphoprotein that
plays a role in cell cycle progression, apoptosis and cellu-
lar transformation. Both MYC and LEF1 act as transcrip-
tion regulators and are involved in many types of cancers
including lung cancer (Nguyen et al. 2009; Dang 2012).
Reversibility of smoking–gene expression associations
Most of the genes were reversible (71 percent) or slowly
reversible (24 percent) after smoking cessation, and only
six genes (4.5 percent) were irreversible. Of the six genes
that were classiﬁed as irreversible, LEF1 is also associated
with smoking in a previous study (Beineke et al. 2012).
The other ﬁve genes are not reported in previous studies
on smoking but need further investigation in order to
explain the differential gene expression between ever
smokers and never smokers. The genes classiﬁed as
‘slowly reversible’ included our top hits GPR15 and
LRRN3. For GPR15, this is in line with a previous study,
while LRRN3 was classiﬁed as both rapidly reversible
(Wan et al. 2012) and slowly reversible (Beineke et al.
2012) in previous studies. GPR15 is a G protein-coupled
receptor that acts as a chemokine receptor for human im-
munodeﬁciency virus types 1 and 2. LRRN3 is a gene cod-
ing for a leucine-rich repeat neuronal 3, and it is highly
expressed in lymphocytes. Both genes were associated with
smoking status in peripheral blood data sets (Wan et al.
2012; Paul &Amundson 2014), andGPR15 has been asso-
ciated with cigarette smoking in three different epigenetic
studies focusing on changes in DNA methylation (Breitling
et al. 2011; Wan et al. 2012; Sun et al. 2013). More
evidence could be obtained with longitudinal data
investigating differences in gene expression levels within in-
dividuals who quit or start smoking.
The fact that we also observed a relation between the
number of cigarettes smoked per day or cotinine levels and
the level of gene expression suggests a dose–response rela-
tionship. The pattern was observed for most genes but was
signiﬁcant for the expression of 28 genes with cigarettes
per day and 10 genes with cotinine. This dose–response rela-
tionship is conﬁrmed in the ex-smokers in whom the gene
expression levels of long-term quitters were often closer to
those of non-smokers than those of short-term quitters.
In order to assess the relative importance of environ-
mental versus genetic sources, we compared the gene
expression patterns in MZ twin pairs discordant for
smoking. The MZ twin design is a powerful design. A
paper of Haque, Gottesman &Wong (2009) reviewed sev-
eral studies that showed substantial epigenetic differences
in MZ twin pairs discordant for psychiatric phenotypes. In
smoking research, only one small study with nine MZ
twin pairs discordant for smoking reported several genes
in which the expression differed in smokers and their
non-smoking co-twins, but none of these genes overlap-
ped with our top results. Of the 132 smoking-related
genes, six genes were differentially expressed in the MZ
pairs consisting of a current smoking twin and a twin
who never smoked: GPR15, PF4, TTC38, ACO63977.1,
ALAS2 and EIF2AK1 (FDR<5 percent for 132 tests).
Gene expression of the six genes was categorized as
reversible (n=3) or slowly reversible (n=3). Those genes
can be considered to show reactive gene expression. The
other 126 genes might also have reactive gene expression,
but considering the small sample size, the power might
be limited. For most of the 132 smoking-related genes
(75 percent), the gene expression effects (upregulated or
downregulated) in the MZ twin pairs were in the same
direction as the effects in the total population. This suggests
that cigarette smoking inﬂuences gene expression.
In addition, we identiﬁed two SNPs (eQTLs of the
smoking-related genes GPR56 and RARRES3), which
were positively associated with the number of cigarettes
per day in the large meta-analyses of the TAG Consor-
tium. Both cis-eQTLs were also found in another eQTL
study in whole blood (Westra et al. 2013). In our sample,
these SNPs were both signiﬁcantly downregulated in
current smokers. GPR56 is a member of the G protein-
coupled receptor family. GPR56 has been shown to have
numerous roles in cell guidance/adhesion as demon-
strated by its roles in tumor inhibition and neuron develop-
ment (Fève et al. 2014). RARRES3 codes for the retinoic
acid receptor responder protein 3. RARRES3 is thought
to act as a tumor suppressor or growth regulator. A recent
study showed that loss of function ofRARRES3 in estrogen
receptor-negative breast cancer cells stimulates their inva-
sive capacity and promotes metastasis to the lung. It is
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remarkable that both genes are associated with tumor
inhibition. Previous studies have demonstrated that the
well-known association between cancer and smoking is
largely explained by causal effects of smoking (Lee &
Hashibe in press), but these results surprisingly suggest
an additional role for pleiotropy (same genes inﬂuencing
both smoking and cancer risk). The TAG consortium GWA
study P-values for these two SNPS were not very low and need
replication in future studies.
Our study was carried out in blood. Although effects
of smoking on gene expression might be present in other
tissues too, like airway epithelial cells, peripheral blood
appears to be a good surrogate tissue for investigating
the effect of smoking on gene expression as it expresses
a large proportion of the genes encoded in the human
genome. Comparison of peripheral blood transcriptome
with genes expressed in nine different human tissue types
revealed that over 80 percent of gene expression was
shared with any given tissue (Liew et al. 2006). The cur-
rent study showed that it is possible to identify gene
expression sites and eQTLs with demonstrable criterion
validity for smoking behavior in peripheral blood draws.
Another important note is that the current study
focused on cigarette smoking; we did not include ques-
tions on other ways to take in nicotine (like e-cigarettes
or water pipe) or on cannabis use (often smoked) in the
biobank study. It should be noted that this information
is available from the longitudinal survey study of the
NTR for a subsample, but especially with gene expression
studies, it is crucial that the information is collected on
the same time as the blood collection.
Lastly, it should be noted that persons who have quit a
long time ago might be healthier than those who quit
recently. We did not ask for the reasons of quitting, so this
might represent a mix of health and non-health related
reasons. However, when we corrected the models for self-
reported health, the health variable did not explain the ob-
served associations between smoking and gene expression.
In conclusion, our results suggest that cigarette smoke
causes differential gene expression. The differentially
expressed genes play a role in several disease pathways
including cancer. Most smoking-related gene expression seem
reversible after smoking cessation. In addition, we found two
genetic variants inﬂuencing gene expression and making
subjects vulnerable for smoking behavior. The current results
are an important step to provide insights into the association
between smoking behavior and differential gene expression.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1 (A) The effect (beta) of the comparison
between current and never on the x-axis, with the effect
(beta) of the comparison between current and ex on the
y-axis for the 132 candidate genes. (B) The effect (beta)
of the comparison between current and never on the x-axis,
with the effect (beta) of the comparison between ex and never
on the y-axis for the 132 candidate genes. Effect is in the
same direction when dots are located in the upper right
square of the plot (both positive) or in the lower left square
of the plot (both negative), which is the case for 100 percent
of the genes in (A) and for 80 percent of the genes in (B).
Figure S2 (A) The effect (beta) of the regression of CPD
on gene expression levels on the y-axis, with the effect
(beta) of the comparison of gene expression levels
between current and never on the x-axis for the 132
smoking-related genes. (B) The effect of the regression
of time since quitting on gene expression levels on the
y-axis with the effect (beta) of the comparison of gene
expression levels between current and never on the x-
axis for the 132 smoking-related genes. (C) The effect
of the comparison of gene expression levels of the 132
candidate genes between monozygotic twin pairs discor-
dant for current smoking on the x-axis, with the effect of
the comparison between current and never smokers in
the total population on the y-axis.
Nextline:
Table S1 Characteristics of the study sample consisting
of smokers, ex-smokers and never smokers.
Table S2 Overview of the 132 smoking-related genes.
Table S3 Pathway analyses for the 132 smoking-
related genes.
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